| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ClearPoint Neuro Inc.$18
-0.91 (-4.87%)
Market Cap
343.08 M
EPS
-1.01
P/E Ratio
-
Value Trade
9.66 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
12.13 M
R&D Expenses
4.52 M
Operating CF
-7.97 M
Total Assets
93.42 M
Total Liabilities
74.58 M
Equity
18.84 M
D/E Ratio
12,345
-7.44 %
Week
4.67 %
1 Month
-20.17 %
3 Month
-15.07 %
6 Month
-39.85 %
5 Year
-61.87 %
All Time
Cash Data
Cash Position
35.59 M
Monthly Burn
2.66 M
Runway
11.7 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
550.97 K
52 Week Range
8.27 - 30.10
% held by Insiders
11.36 %
% held by Institutions
43.71 %
Enterprise Value
371.08 M
Total Shares
29.66 M
Short %
18.5 %
Float Shares
27.26 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CLPT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CLPT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CLPTClearPoint Neuro Reports First Quarter 2026 Results Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth
ClearPoint Neuro reported strong financial growth in the first quarter of 2026, achieving record revenues of $12.1 million, representing a 43% increase year-over-year. The company experienced a 25% organic growth in its devices segment and expansion in its global installed base to over 175 centers. Despite the positive performance, operating expenses rose significantly, reflecting higher costs associated with company growth, while cash reserves decreased compared to the previous quarter. ClearPoint remains optimistic about continued progress across its core growth strategies and achieving future revenue targets.
Read more →CLPTClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro has announced the receipt of a Medical Device License from Health Canada for its Neuro Navigation System. This approval enhances the company's drug delivery ecosystem and allows Canadian neurosurgery centers to utilize their advanced image-guidance workflows. The integration of Canadian clinical trial sites into ClearPoint's global infrastructure aims to streamline processes and support the goal of enabling 20,000 cell and gene therapy procedures annually.
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results Record Revenue and IRRAS Holdings Acquisition Highlight the Company's ‘Fast. Forward.' Strategy
ClearPoint Neuro, Inc. reported a record revenue of $10.4 million in the fourth quarter of 2025, marking a 34% growth compared to the previous year. The successful acquisition of IRRAS Holdings has expanded the company’s portfolio into neurocritical care, enabling access to a new market. Overall revenue for 2025 reached $37.0 million, indicating consistent growth over the past eleven years. The company expects continued expansion, projecting revenues between $52.0 - $56.0 million for 2026, while addressing increased operating expenses resulting from the acquisition and development efforts.
Read more →CLPTClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe
ClearPoint Neuro has received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2, allowing it to offer a unified navigation platform in Europe. This new version enhances surgical capabilities by introducing an intraoperative CT workflow, making precision-guided neurosurgery more accessible. The software aims to reduce operational costs and improve training consistency across global markets.
Read more →CLPTClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million
ClearPoint Neuro, Inc. announced preliminary unaudited revenue growth for Q4 2025, reporting approximately $10.4 million, a 20% increase compared to Q4 2024. The company expects continued expansion in its four growth markets for 2026, projecting total revenues between $54 million and $60 million. The results are preliminary and subject to revision after the annual audit, highlighting potential uncertainties in future performance. ClearPoint is focused on integrating its recent acquisition of the IRRAflow product line, which is expected to contribute to growth.
Read more →CLPTClearPoint Neuro Completes Acquisition of IRRAS Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation
ClearPoint Neuro has successfully completed its acquisition of IRRAS Holdings, enhancing its capabilities in CNS drug delivery. The $5 million cash transaction involved the issuance of shares and outlines a revenue share model on certain sales. With the debut of the IRRAflow technology, ClearPoint aims to strengthen its position in neurocritical care. The merger is viewed as a strategic move to expand market reach and improve patient-centric services.
Read more →CLPTClearPoint Neuro Reports Third Quarter 2025 Results Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization
ClearPoint Neuro reported its third-quarter financial results for 2025, highlighting a revenue increase of 9% compared to the previous year. The company is enhancing its capabilities with the opening of a new pre-clinical facility and has received FDA clearance for its Laser Therapy System, broadening market access. ClearPoint also announced plans to acquire IRRAS Holdings, which will expand its offerings in neurocritical care. The firm aims to support more cell and gene therapy trials by activating additional specialized treatment centers.
Read more →CLPTClearPoint Neuro Announces Agreement to Acquire IRRAS Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.
ClearPoint Neuro has announced an agreement to acquire IRRAS Holdings, which specializes in neurocritical care technologies. This acquisition aims to expand ClearPoint's drug delivery portfolio and gain access to a global market estimated at $0.5 billion for the treatment of intracranial bleeding. The deal is expected to enhance operational scale and includes a cash payment along with shares of ClearPoint common stock. Completion of the merger is contingent upon IRRAS shareholder approval, with expectations of significant revenue growth for 2026.
Read more →CLPTClearPoint Neuro Reports Second Quarter 2025 Results Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy
ClearPoint Neuro reported record financial results for the second quarter of 2025, achieving $9.2 million in revenue, which represents a 17% increase compared to the same quarter last year. The company experienced significant growth in neurosurgery navigation and therapy revenue, driven by new product offerings. ClearPoint also secured a substantial cash infusion through a note financing arrangement and a stock purchase agreement, ultimately enhancing its cash reserves to $41.5 million. Despite positive financial results, there was a slight decrease in gross margin and an increase in operating expenses.
Read more →CLPTClearPoint Neuro Reports First Quarter 2025 Results Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products
ClearPoint Neuro, Inc. reported a record revenue of $8.5 million for the first quarter of 2025, marking an 11% increase from the same period in 2024. The company experienced significant growth in its single-use navigation and therapy products, with a notable 70% increase in neurosurgery revenue. Additionally, ClearPoint received FDA clearance for its new software, now available in the market, which is driving revenue and usage growth. Despite increased operating expenses and a decline in cash reserves, the company remains optimistic about its financial outlook for the year.
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35%
ClearPoint Neuro, Inc. reported its fourth quarter and full year 2024 results, achieving record revenue of $31.4 million, marking a 31% growth compared to 2023. The company also noted a significant decrease in operational cash burn by 35%, reflecting improved financial management. Key highlights included the activation of 25 new global centers, further supporting their clinical trials and partnerships. Despite increased operating expenses due to higher personnel costs, ClearPoint remains optimistic about future growth and upcoming product launches. They project continued revenue growth for 2025, estimating between $36 million and $41 million.
Read more →CLPTClearPoint Neuro Reports Third Quarter 2024 Results Achieved Record Revenue and Growth of 41% Operational Cash Burn Reduced to $1.2 Million
ClearPoint Neuro reported impressive financial results for Q3 2024, achieving a record revenue of $8.1 million, representing a 41% increase from the same period last year. The company also reduced its operational cash burn to $1.2 million, a significant 33% decrease year-over-year. Noteworthy advancements include the accelerated growth of its SmartFrame OR platform and PRISM laser therapy systems, contributing to an overall doubling of product revenue. The company remains optimistic, maintaining its full-year revenue outlook of $30 to $33 million.
Read more →CLPTClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024
ClearPoint Neuro, Inc. plans to release its financial results for the third quarter of 2024 on November 7, 2024, after market close. Investors and analysts are invited to participate in a live conference call at 4:30 PM Eastern Time. The company, involved in device, cell, and gene therapy solutions, emphasizes its established regulatory approvals and global operations.
Read more →CLPTClearPoint Neuro Announces Early Repayment of $10 Million Note
ClearPoint Neuro, Inc. has announced the early repayment of a $10 million convertible note to PTC Therapeutics, which was originally set to mature in January 2025. This repayment reflects ClearPoint's confidence in its business and ensures the removal of debt from its balance sheet, thus preventing dilution. The CEO highlighted the ongoing collaboration with PTC Therapeutics, particularly regarding the submission of a Biologics License Application for Upstaza, an investigational treatment currently under FDA review.
Read more →CLPTClearPoint Neuro Reports Second Quarter 2024 Results Second Quarter Revenue Growth +32% Record Revenue Achieved
ClearPoint Neuro reported a remarkable second quarter for 2024, achieving a record revenue of $7.9 million, a 32% increase from the previous year. The product revenue saw significant growth, doubling in some segments and led primarily by the launch of new technologies such as the SmartFrame OR. The company has raised its full-year revenue guidance to between $30.0 and $33.0 million. Despite the challenges of paused collaborations and increased operating expenses, the overall financial health appears strong with reduced cash burn rates.
Read more →CLPTClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024
ClearPoint Neuro, a company specializing in device, cell, and gene therapy technologies, announced it will release its financial results for the second quarter of 2024 on August 7. The company invites investors and analysts to participate in a subsequent conference call, which will also be available for replay. ClearPoint's flagship Neuro Navigation System has received significant regulatory approvals, underscoring its commitment to engaging with the healthcare sector globally. However, the company acknowledges various risks associated with forward-looking statements regarding its future performance and market acceptance.
Read more →CLPTClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
ClearPoint Neuro has congratulated its partner Aspen Neuroscience for using its ClearPoint Navigation System in the ASPIRO Phase 1/2a clinical trial. This trial focuses on the safety and tolerability of ANPD001, a regenerative therapy for patients with Parkinson’s Disease. The unique approach involves using the ClearPoint system to navigate and deliver dopaminergic neuron precursor cells directly to the brain. The partnership aims to reduce surgical variability and enhance the efficacy of the treatment across all enrolled patients.
Read more →CLPTClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM 3T Laser Therapy System
ClearPoint Neuro, Inc. has announced the full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery. This launch aims to enhance the accessibility and efficiency of Deep Brain Stimulation (DBS) procedures, which have traditionally been performed in specialized centers. The new technology is expected to allow a larger number of hospitals to conduct DBS, potentially increasing patient treatment rates significantly. Leading neurosurgeons have praised the innovative solutions, indicating a positive impact on clinical practice and patient outcomes.
Read more →CLPTClearPoint Neuro Reports First Quarter 2024 Results First Quarter Revenue Growth +41% Record Revenue Achieved
ClearPoint Neuro reported a record revenue of $7.6 million for the first quarter of 2024, representing a 41% increase year-over-year. Key highlights include a significant rise in biologics and drug delivery revenue, and the activation of a record eight new hospital customers. However, the company also faced challenges, including an 18% decline in revenue from functional neurosurgery navigation and increases in overall operating expenses. The company has reaffirmed its 2024 revenue outlook of $28 million to $32 million.
Read more →CLPTClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
ClearPoint Neuro, Inc. announced it will present original research and exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore from May 7-11. The company will present key studies focusing on MRI-guided gene and cell therapy delivery. In addition to its presentations, ClearPoint’s technology will be featured in partner posters and presentations, enhancing its visibility at the conference. ClearPoint's Chief Business Officer expressed that this event offers significant opportunities for collaboration with existing partners and potential new customers.
Read more →CLPTClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory
ClearPoint Neuro, Inc. has announced FDA clearance for its new Prism Bone Anchor Accessory, marking its second product introduction in 2024. This accessory is designed to be used with existing stereotactic systems for accurate positioning during neurosurgical procedures. The company is looking to expand its reach into operating rooms, as it responds to challenges with MRI access in hospital settings. A limited market release is set for the second quarter of 2024, with a full launch expected in the latter half of the year.
Read more →CLPTClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System
ClearPoint Neuro has initiated a Limited Market Release for its SmartFrame OR Stereotactic System, enabling procedures in operating rooms, which the company describes as a key strategic move. With over ten cases completed within the first month, the product offers potential for significant market expansion by making procedures feasible where MRI guidance was previously unavailable. It is designed to work seamlessly with existing hospital equipment, positioning ClearPoint for a swift full market release expected in the latter half of 2024. This release is anticipated to generate meaningful revenue for the company.
Read more →CLPTClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024
ClearPoint Neuro, Inc. (Nasdaq: CLPT) has announced the release of its financial results for the first quarter of 2024, scheduled for May 7. Investors and analysts can participate in the conference call or access a live broadcast. The announcement highlights ClearPoint's collaboration with various healthcare centers and its FDA-cleared flagship neuro navigation system, while also addressing potential risks related to market dynamics and operational challenges.
Read more →CLPTClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
ClearPoint Neuro has announced that its partner, AviadoBio, has successfully treated the first patient in the ASPIRE-FTD clinical trial evaluating AVB-101 for frontotemporal dementia with GRN mutations. The Phase 1/2 trial aims to explore the efficacy of this gene therapy, which targets a serious form of early-onset dementia. The treatment is crucial as it seeks to mitigate systemic exposure while delivering the therapy accurately to the thalamus. This collaboration highlights ClearPoint Neuro's capabilities in supporting gene therapy applications.
Read more →CLPTClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
ClearPoint Neuro has congratulated its partner PTC Therapeutics on the successful submission of a Biologics License Application (BLA) to the FDA for Upstaza™. This investigational treatment aims to address AADC Deficiency, a severe early-onset genetic disorder that significantly affects children's lives. If approved, Upstaza™ would be the first therapy to treat this condition in the United States, marking a notable advancement for affected patients and their families. ClearPoint Neuro underscores its commitment to improving outcomes in the AADC Deficiency community through this collaboration.
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results Release Includes Commentary on Early 2024 Progress
ClearPoint Neuro reported a 32% increase in revenue for Q4 2023, totaling $6.8 million, marking the ninth consecutive year of growth. The company also completed a successful equity offering, generating approximately $15 million to enhance its financial standing. Despite these positive results, ClearPoint faced challenges with a decrease in gross margin and some declines in specific revenue segments. The company remains optimistic, reaffirming its revenue guidance for 2024 between $28 million and $32 million.
Read more →CLPTClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
ClearPoint Neuro, Inc. has announced it will release its financial results for the fourth quarter and full year of 2023 on March 12, 2024. Investors and analysts can tune in to a live broadcast of the results, with options for participation via telephone and an archive available afterward. The company is involved in device, cell, and gene therapy enabling technologies, serving various international markets. Detailed financial outlook and performance expectations will be discussed during the call, providing insights into the company's strategic direction.
Read more →CLPTClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
ClearPoint Neuro, Inc. announced the pricing of a public offering of 2,307,694 shares of its common stock at $6.50 per share. The company also granted the underwriter a 30-day option to purchase an additional 346,154 shares. Proceeds from the offering will be used for general corporate purposes, including research and development, acquisitions, and debt repayment. The offering is expected to close on March 4, 2024, subject to customary closing conditions.
Read more →CLPTClearPoint Neuro Launches Proposed Public Offering of Common Stock
ClearPoint Neuro, Inc. has announced a proposed underwritten public offering of common stock, with plans to grant underwriters a 30-day option for additional shares. The offering is contingent upon market conditions and uncertainties regarding its completion and terms. An effective shelf registration statement has been filed with the SEC, but investors are cautioned about potential risks associated with the offering. The company remains active in its sector, having engaged in numerous procedures supported by clinical specialists globally.
Read more →CLPTClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model
ClearPoint Neuro has announced FDA clearance for its new ClearPoint 2.2 Software, which integrates the Maestro Brain Model. This software has successfully undergone first-in-human clinical cases, signaling a significant advancement for MRI-guided neuro interventions. Additionally, a validation study published in the journal 'NeuroImage' supports the software's effective segmentation capabilities. The company anticipates a full market release in the latter half of 2024.
Read more →CLPTClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo
ClearPoint Neuro, Inc. announced the installation and successful first procedure of its ClearPoint Prism Neuro Laser Therapy System at Kaleida Health in Buffalo, New York. The procedure, performed by Dr. Jonathan Riley, showcased the effectiveness of the new technology in providing minimally invasive neurosurgical options. ClearPoint's innovative non-cooled laser applicator is expected to enhance workflow efficiency in future procedures. The company looks to expand its product market release later this year.
Read more →CLPTClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe
ClearPoint Neuro, Inc. has announced the successful receipt of European Medical Device Regulation (EU MDR) clearance for its manual SmartTwist MR Hand Drill and SmartTip MR Drill Kit. This certification marks the company's compliance with updated European standards, thereby allowing the shipment of products from its new Carlsbad, California facility to Europe. The EU MDR introduces stricter regulations compared to the previous Medical Device Directive, emphasizing the significance of safety and risk management in the medical device industry.
Read more →CLPTClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System
ClearPoint Neuro has received FDA 510(k) clearance for its SmartFrame OR Stereotactic System, which enhances surgical navigation for neurological procedures. This system, comprising the SmartFrame OR and ClearPointer Optical Navigation Wand, facilitates procedures such as biopsies and catheter placements without needing MRI. The launch of the SmartFrame OR is planned for a limited market release in the first half of 2024, with a full market rollout to follow later in the year. This innovation marks a strategic move for ClearPoint Neuro, allowing it to address a broader market of surgical procedures.
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue
ClearPoint Neuro, Inc. has announced its preliminary, unaudited financial results for the fourth quarter and full year 2023, reporting a 32% increase in quarterly revenue and a total of approximately $24 million for the year. The company anticipates revenue growth for 2024, expecting to generate between $28 million and $32 million. Strategic product launches and new revenue streams are planned, but the company noted that its financial results are subject to revision pending an annual audit. Additionally, several risks, including supply chain disruptions and market acceptance of new products, may impact future performance.
Read more →CLPTClearPoint Neuro Inc's Innovative Pipeline Products Under Analysis in New 2023 Update
ClearPoint Neuro Inc's product pipeline has been extensively documented in a new report that analyzes the company's innovative technologies for treating neuro disorders. The report provides detailed insights into various pipeline products and ongoing clinical trials, enhancing strategic decision-making capabilities for stakeholders. Additionally, ClearPoint has made notable strides, including recent regulatory clearances for their neuro navigation systems, highlighting their commitment to advancing medical technology.
Read more →CLPTClearPoint Neuro Reports Third Quarter 2023 Results Biologics Drug Delivery Growing 55% Q3 Operational Cash Burn of $1.8M
ClearPoint Neuro reported its third-quarter financial results for 2023, showcasing a robust increase in revenue and a significant growth in biologics and drug delivery sales. Total revenue reached $5.8 million, marking a 12% year-over-year increase, while biologics and drug delivery revenue surged 55% to $3.5 million. The company also successfully reduced its operational cash burn to $1.8 million, the lowest quarterly figure since 2020, and has transitioned its manufacturing operations to a new facility. However, the report highlighted decreases in functional neurosurgery navigation and therapy revenue and gross margin, raising some concerns about ongoing profitability.
Read more →CLPTClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023
ClearPoint Neuro, Inc. announced it will release its financial results for the third quarter of 2023 on November 9, 2023. Following the release, the company will conduct a live conference call for investors and analysts, providing insights into its financial performance. ClearPoint Neuro specializes in neurological disorder therapies and has established numerous partnerships with pharmaceutical and biotech companies, emphasizing its role in delivering brain-targeted treatments. The company highlights the importance of understanding risks that may impact future performance.
Read more →CLPTClearPoint Neuro Reports Second Quarter 2023 Results Biologics Drug Delivery growing +40% Company Reaffirms 2023 Revenue Forecast
ClearPoint Neuro, Inc. reported strong financial results for Q2 2023, with a record quarterly revenue of $6.0 million, reflecting a 14% increase year-over-year. Notably, revenue from biologics and drug delivery surged by 40% to $3.4 million. The company has also reaffirmed its revenue outlook for the full year 2023, projecting between $25.0 and $27.0 million. However, challenges remain as gross margins decreased due to increased costs and a shift towards lower-margin services, alongside higher operating expenses.
Read more →CLPTClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023
ClearPoint Neuro, Inc. is set to announce its financial results for the second quarter of 2023 on August 8. Investors and analysts are invited to participate in a live conference call where the results will be discussed. The company is focused on improving therapy delivery for complex neurological disorders through its ClearPoint Neuro Navigation System, which is already installed in over 65 sites worldwide. However, ClearPoint is aware of various risks that could impact their performance, including economic conditions and market acceptance of their products.
Read more →CLPTClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
ClearPoint Neuro has entered into a multi-year license agreement with UCB to collaborate on drug delivery platforms focusing on UCB's gene therapy portfolio. This partnership positions ClearPoint Neuro as a key player in enabling innovative techniques for drug delivery to the brain. The agreement includes milestone payments for ClearPoint Neuro as UCB develops and commercializes these therapies. Both companies express optimism regarding the collaboration's potential to advance research and development in neurology.
Read more →CLPTClearPoint Neuro to Present at the B. Riley Securities 2023 Institutional Investor Conference
ClearPoint Neuro, Inc. (CLPT) will present at the B. Riley Securities 2023 Institutional Investor Conference on May 24, 2023. The company's technology focuses on enabling precision therapies for complex neurological disorders. ClearPoint's product portfolio includes various applications such as deep brain stimulation and gene therapy delivery. With an established presence across more than 65 sites worldwide, the company continues to expand its partnerships in the biopharma industry.
Read more →CLPTClearPoint Neuro Reports First Quarter 2023 Results Biologics Drug Delivery growing +24% Company Reaffirms 2023 Revenue Forecast
ClearPoint Neuro, Inc. reported its first quarter 2023 results, showcasing an 8% increase in total revenue to $5.4 million, driven by a significant 24% growth in biologics and drug delivery revenue. The company reaffirmed its revenue forecast for the year, expecting between $25 million and $27 million. Despite these positive developments, ClearPoint faced challenges with rising operating expenses and a decline in gross margins. Additionally, ClearPoint made strides in expanding its partnerships and operational capabilities during the quarter.
Read more →CLPTClearPoint Neuro to Present Investigational Research and Showcase Novel Innovations at the 26th American Society of Gene & Cell Therapy Annual Meeting in Los Angeles
ClearPoint Neuro, Inc. announced its participation in the 26th American Society of Gene and Cell Therapy Annual Meeting in Los Angeles from May 16 to 20, where it will present original research and showcase novel innovations. Noteworthy presentations include advances in gene therapy delivery methods and the introduction of the ClearPoint Maestro Brain Model. The company aims to demonstrate how their tools can streamline drug delivery in CNS therapies. ClearPoint's reputation is bolstered by previous interest from pharmaceutical partners, indicating potential market engagement.
Read more →CLPTClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023
ClearPoint Neuro, Inc. will announce its financial results for the first quarter of 2023 on May 11, 2023, after market close. A live conference call will be held at 4:30 PM ET that day for investors and analysts to review these results. The call will also be available via a replay for those who cannot attend live. ClearPoint aims to improve neurological therapy delivery through its established navigation systems, which have received FDA clearance and are installed globally.
Read more →CLPTClearPoint Neuro to Showcase Two Novel Innovations at AANS 2023: ClearPoint Maestro Brain Model and ClearPoint Prism™ Neuro Laser Therapy System
ClearPoint Neuro is set to exhibit two innovative products at the AANS 2023 Annual Meeting: the ClearPoint Maestro Brain Model and the ClearPoint Prism Neuro Laser Therapy System. The Maestro model is designed to enhance the precision of brain surgeries under MRI guidance, while the Prism system is currently part of a clinical trial for Glioblastoma treatment. Both products reflect the company's commitment to improving treatment options for complex neurological disorders and are expected to assist neurosurgeons in their practice. The exhibition takes place from April 21 to April 23 in Los Angeles, CA.
Read more →CLPTClearPoint Neuro Announces Agreement with NE Scientific to Integrate Gene Therapy Infusion Coverage Tool into ClearPoint Maestro Brain Model
ClearPoint Neuro has formed an exclusive global agreement with NE Scientific to develop a GPU-accelerated software solution for modeling drug infusions using its ClearPoint SmartFlow® cannula. This collaboration aims to enable real-time patient-specific infusion simulations that predict therapeutic agent distribution before surgical procedures. The integration with the ClearPoint Maestro Brain Model is set to optimize infusion parameters, enhancing surgical precision and patient outcomes.
Read more →CLPTClearPoint Neuro Announces ANVISA Approval of Neuro Navigation Portfolio in Brazil
ClearPoint Neuro has received approval from Brazil's regulatory agency ANVISA for its Neuro Navigation portfolio. This approval is a significant milestone for the company, marking its first entry into the Latin American market. The technology is expected to enhance treatment options for neurological disorders, including brain cancer, and improve procedures like deep brain stimulation. Brazilian neurosurgeons are optimistic about utilizing the system for advanced medical treatments, reflecting the potential impact on patient care.
Read more →CLPTClearPoint Neuro Extends Software License and Research Agreement with Philips to Include Fully Automatic Subnuclei Segmentation for DBS
ClearPoint Neuro has expanded its software license and research agreement with Philips, enhancing the Maestro Brain Model to include fully automatic subnuclei segmentation for deep brain stimulation. This extension aims to improve target identification and trajectory planning during neurosurgeries by integrating technologies for MRI and CT scans. The operational efficiency and speed of the ClearPoint platform are expected to optimize surgical processes and potentially benefit patient-specific interventions. The collaboration demonstrates ClearPoint's commitment to advancing neuro-navigation technology and its applications in complex neurological disorders.
Read more →CLPTClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform
ClearPoint Neuro, Inc. has announced an exclusive multi-year licensing agreement with UC San Francisco to develop a radially branching cellular delivery device. This device aims to guide the delivery of biologic therapies such as stem cells and gene therapy to targeted locations in the brain with real-time imaging. The partnership is expected to enhance the efficacy of treatments for neurological disorders, including Parkinson's disease. Pre-clinical results have shown promise with the device, and ClearPoint aims to bring this innovative platform to market in various geographies.
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results Company Reports Record Revenues
ClearPoint Neuro reported its financial results for the fourth quarter and full year of 2022, achieving a record revenue of $20.6 million, a 26% increase over the previous year. The company attributed its growth to increased revenue from biologics and drug delivery, as well as a successful expansion of its partner network. However, gross margins declined slightly, and operating expenses increased, raising some concerns about financial management. The CEO expressed optimism for 2023, expecting continued revenue growth influenced by ongoing partnerships and FDA approvals.
Read more →CLPTClearPoint Neuro to Announce Fourth Quarter and Full Year 2022 Revenue Results March 1, 2023
ClearPoint Neuro, Inc. is set to announce its financial results for the fourth quarter and full year 2022 on March 1, 2023. Following the announcement, a live broadcast will summarize the results, with access for investors and analysts by telephone or online. As a company focused on neurological disorder therapies, ClearPoint Neuro has established a significant market presence, supported by partnerships with numerous pharmaceutical companies. However, various uncertainties and risks could impact its future performance.
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue
ClearPoint Neuro reported its preliminary unaudited financial results for Q4 and full year 2022, highlighting a 21% revenue increase in Q4 and a record $20.6 million in annual revenue. The company provided optimism for 2023 with expected revenue growth between 22% and 31%. Despite underwhelming recognition of revenue in Q4, the company noted a significant backlog of orders. ClearPoint also plans to submit a Biologics License Application and expand its global presence through partnerships and new clinical trials.
Read more →CLPTClearPoint Neuro to Present at Upcoming Investor Conferences
SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the following investor con
Read more →CLPTClearPoint Neuro Reports Third Quarter 2022 Results Company Reaffirms 2022 Revenue Forecast
ClearPoint Neuro Reports Third Quarter 2022 Results Company Reaffirms 2022 Revenue Forecast SOLANA BEACH, CA, November 8, 2022 - ClearPoint Neuro, Inc. (Nasdaq CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, toda
Read more →CLPTClearPoint Neuro to Announce Third Quarter 2022 Results November 8, 2022
SOLANA BEACH, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 third quar
Read more →CLPTClearPoint Neuro Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced its Swedish partner, Clinical Laserthermia Systems (CLS), has
Read more →CLPTClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer
ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer SOLANA BEACH, CA, September 20, 2022 - ClearPoint Neuro, Inc. (Nasdaq CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announce
Read more →CLPTClearPoint Neuro Announces FDA Clearance for Software Version 2.1
SOLANA BEACH, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has obtained 510(k) clearance for version 2.1 of the
Read more →CLPTClearPoint Neuro Announces FDA Clearance for ClearPoint Maestro™ Brain Model
SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it has received 510(k) clearance for its ClearPoint Maestro™ B
Read more →CLPTClearPoint Neuro Reports Second Quarter 2022 Results Record Quarterly Revenue Achieved Company Reaffirms 2022 Revenue Forecast
ClearPoint Neuro Reports Second Quarter 2022 Results Record Quarterly Revenue Achieved Company Reaffirms 2022 Revenue Forecast SOLANA BEACH, CA, August 9, 2022 - ClearPoint Neuro, Inc. (Nasdaq CLPT) (the "Company"), a global therapy-enabling platform company providing navigatio
Read more →CLPTClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs
SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice Pr
Read more →CLPTClearPoint Neuro to Announce Second Quarter 2022 Results August 9, 2022
SOLANA BEACH, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 second qua
Read more →CLPTClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC Deficiency
SOLANA BEACH, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, congratulates partner PTC Therapeutics for being granted marketing authorizati
Read more →CLPTClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy
SOLANA BEACH, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain today congratulates partner Neurona Therapeutics on dosing the first patient in
Read more →CLPTClearPoint Neuro Announces Receipt of MDSAP Certification
SOLANA BEACH, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the receipt of certification for the Medical Device Single Aud
Read more →CLPTClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency
SOLANA BEACH, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner PTC Therapeutics for receiving a positive opinion f
Read more →CLPTClearPoint Neuro to Present Investigational Research and Exhibit at the American Society of Gene & Cell Therapy Annual Meeting in Washington, DC
SOLANA BEACH, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it will present investigational research and exhibit at the 25t
Read more →CLPTClearPoint Neuro Reports First Quarter 2022 Results
ClearPoint Neuro Reports First Quarter 2022 Results SOLANA BEACH, CA, May 11, 2022 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its firs
Read more →CLPTClearPoint Neuro and Higgs Boson Health Announce Collaboration
SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a collaboration with Higgs Boson Health (Durham, NC) to bring t
Read more →CLPTClearPoint Neuro Announces FDA Clearance of the SmartFrame Array™ Version 1.1
SOLANA BEACH, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has received FDA clearance for version 1.1 of its nex
Read more →CLPTClearPoint Neuro Expands Software License and Research Agreement with Philips to Power Expansion of the ClearPoint Platform into the Operating Room
SOLANA BEACH, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced expansion of their worldwide license and research agreement w
Read more →CLPTClearPoint Neuro to Announce First Quarter 2022 Results May 11, 2022
SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 first qua
Read more →CLPTClearPoint Neuro to Present at the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference
SOLANA BEACH, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the B. Riley Securities D
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results Company Reports Record Revenues
ClearPoint Neuro Reports Fourth Quarter and Full-Year Company Reports Record Revenues SOLANA BEACH, CA, March 1, 2022 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today anno
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full Year 2021 Preliminary Revenue Results and Guidance for Full Year 2022 Revenue Company to Hold Earnings Call on
ClearPoint Neuro Reports Fourth Quarter and Full Year 2021 Preliminary Revenue Results and Guidance for Full Year 2022 Revenue Company to Hold Earnings Call on March 1, 2022 SOLANA BEACH, CA, February 15, 2022 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global
Read more →CLPTClearPoint Neuro to Participate at the H.C. Wainwright BIOCONNECT Virtual Conference
SOLANA BEACH, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will participate at the H.C. Wainwright BI
Read more →CLPTClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System
SOLANA BEACH, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Blackrock Neurotech for receiving Breakthrough Dev
Read more →CLPTClearPoint Neuro Reports Third Quarter 2021 Results Record Revenue Achieved; Company Reaffirms 2021 Revenue Forecast
ClearPoint Neuro Reports Third Quarter 2021 Results Record Revenue Achieved; Company Reaffirms 2021 Revenue SOLANA BEACH, CA, November 9, 2021 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery
Read more →CLPTClearPoint Neuro Congratulates Neurona Therapeutics on IND Clearance for Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients
SOLANA BEACH, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Neurona Therapeutics on clearance by the U.S. Food
Read more →CLPTClearPoint Neuro to Present at the 2021 Stifel Virtual Healthcare Conference
SOLANA BEACH, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the 2021 Stifel Virtual He
Read more →CLPTInternationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors
Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors SOLANA BEACH, CA, November 2, 2021 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-enabling platform company providing naviga
Read more →CLPTClearPoint Neuro to Announce Third Quarter 2021 Results November 9, 2021
SOLANA BEACH, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2021 third quar
Read more →CLPTClearPoint Neuro Reports Second Quarter 2021 Results Record Case Volume Supported Clinically During the Quarter
ClearPoint Neuro Reports Second Quarter 2021 Results Record Case Volume Supported Clinically During the Quarter SOLANA BEACH, CA, August 10, 2021 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delive
Read more →CLPTClearPoint Neuro, Inc. Announces Strategic and Commercial Partnership with European Surgical Equipment Leader adeor medical AG
SOLANA BEACH, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it has entered into a strategic and commercial partnership with German-based s
Read more →CLPTClearPoint Neuro to Announce Second Quarter 2021 Results August 10, 2021
SOLANA BEACH, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2021 second qua
Read more →CLPTClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors
SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Compa
Read more →CLPTClearPoint Neuro, Inc. Executive Officer and Director Stock Ownership Guidelines As adopted on
ClearPoint Neuro, Inc. Executive Officer and Director Stock Ownership Guidelines As adopted on June 25, 2021 The Board of Directors (the "Board") of ClearPoint Neuro, Inc. ("CLPT" or the "Company") has adopted these stock ownership guidelines to further align the interest of
Read more →CLPTClearPoint Neuro Set to Join Russell 3000 Index
SOLANA BEACH, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is set to join the broad-market Russell 3000 Index at the conclusion of the 20
Read more →CLPTClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease
SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates BlueRock Therapeutics, a clinical stage biopharmaceutical
Read more →CLPTClearPoint Neuro to Present at the UBS Global Healthcare Virtual Conference
SOLANA BEACH, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the UBS Global Healthcare V
Read more →CLPTClearPoint Neuro, Inc. Announces First-in-Human Cases of the SmartFrame Array™ Neuro Navigation System and Software
SOLANA BEACH, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling company providing navigation and delivery to the brain, today announced the first human cases of the SmartFrame Array Neuro Navigation System an
Read more →CLPTClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance of the SmartFrame Array'
ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, FDA Clearance of the SmartFrame Array' SOLANA BEACH, CA, May 11, 2021 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to
Read more →CLPTClearPoint Neuro Announces Partnership With D&K Engineering for Development of Robotic System for the MRI Suite and Operating Room
SOLANA BEACH, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a partnership with San Diego-based D&K Engineering for the cont
Read more →CLPTClearPoint Neuro to Announce First Quarter 2021 Results May 11, 2021
SOLANA BEACH, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2021 first qua
Read more →CLPTClearPoint Neuro, Inc. Congratulates Voyager Therapeutics on FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
SOLANA BEACH, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates Voyager Therapeutics on receiving FDA clearance of the IN
Read more →CLPTClearPoint Neuro Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOLANA BEACH, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that on September 14, 2020, the Company’s Board of Directors
Read more →CLPTClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.
SOLANA BEACH, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the upcoming retirement of John N. Spencer, Jr. from its Boar
Read more →CLPTClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates uniQure N.V. on the early completion of patient enrollment in t
Read more →CLPTClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel
IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full-Year 2020 Results Company Reports Record Revenues IRVINE, CA
ClearPoint Neuro Reports Fourth Quarter and Full-Year Company Reports Record Revenues IRVINE, CA, March 4, 2021 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced
Read more →CLPTClearPoint Neuro Announces Closing of Public Offering of 2,127,660 Shares of Common Stock
IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the closing of its previously disclosed public offering of common st
Read more →CLPTClearPoint Neuro to Announce Fourth Quarter and Full Year 2020 Results on March 4, 2021
IRVINE, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2020 fourth quarter a
Read more →CLPTClearPoint Neuro Announces Pricing of Public Offering of 1,850,140 Shares of Common Stock
IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the pricing of its underwritten public offering of 1,850,140 shares
Read more →CLPTClearPoint Neuro, Inc. Announces License and Research Agreement with Philips
Collaboration will Enable ClearPoint to Develop and Launch the ClearPoint ‘Maestro™’ Brain Model by 2022 IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and d
Read more →CLPTClearPoint Neuro, Inc. Announces Multi-Product Joint Development & Option Agreement with Blackrock Microsystems
IRVINE, Calif. and SALT LAKE CITY, Utah, Feb. 11, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a multi-product joint development and optio
Read more →CLPTClearPoint Neuro, Inc. Announces Appointment of R. John Fletcher as Chairman of the Board of Directors
IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that R. John Fletcher has been appointed Chairman of the Company’s Board of Directors. The prior Chairman, Kimble L. Jenkins, retired from the Chairman role, wh
Read more →CLPTClearPoint Neuro, Inc. Announces Appointment of R. John Fletcher as Chairman of the Board of Directors IRVINE, CA
ClearPoint Neuro, Inc. Announces Appointment of R. John Fletcher as Chairman of the Board of Directors IRVINE, CA, February 5, 2021 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company") today announced that R. John Fletcher has been appointed Chairman of the Company's Board
Read more →CLPTClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners
IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ernesto Salegio, PhD will join the Company as Vice President, Segment Leader Tr
Read more →CLPTClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint 2.0 Software in Europe
IRVINE, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported the first utilization in Europe of its Version 2.0 software, together with the ClearP
Read more →CLPTClearPoint Neuro, Inc. Reports Record Revenue in Preliminary Fourth Quarter 2020 Results IRVINE, CA
ClearPoint Neuro, Inc. Reports Record Revenue in Preliminary Fourth Quarter 2020 Results IRVINE, CA, January 12, 2021 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today repo
Read more →CLPTClearPoint Neuro, Inc. Reports Record Revenue in Preliminary Fourth Quarter 2020 Results
IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported preliminary unaudited revenue results for the quarter and full year e
Read more →CLPTClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms
IRVINE, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an amendment to its January 2020 secured convertible note financing
Read more →CLPTClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms Represents Draw of Additional Proceeds from Petrichor Announced in January 2020 IRVINE, CA
ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms Represents Draw of Additional Proceeds from Petrichor Announced IRVINE, CA, December 29, 2020 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-
Read more →CLPTClearPoint Neuro Completes 4,000th ClearPoint Neuro Navigation Procedure
IRVINE, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a leader in image-guided stereotactic neurosurgery, announced that its 4,000th neurosurgical procedure using the ClearPoint Neuro Navigation System was completed earlier this month at Dartmou
Read more →CLPTClearPoint Neuro Reports Third Quarter 2020 Results Revenue Reaches a Record $3.5 million IRVINE, CA
ClearPoint Neuro Reports Third Quarter 2020 Results a Record $3.5 million IRVINE, CA, November 10, 2020 - ClearPoint Neuro, Inc. (Nasdaq: CLPT), a medical device company with a portfolio of products focused on enabling therapies for neurological disorders, today announced fin
Read more →CLPTClearPoint Neuro to Announce Third Quarter 2020 Results on November 10
IRVINE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 third quarter, which ended September 30, 2020, on Tuesday, November 10, 2020 after the market close. The Com
Read more →CLPTClearPoint Neuro Announces Transition Plan for New Chief Financial Officer Danilo D'Alessandro will Succeed Harold A. Hurwitz who Plans to Retire in 2021 IRVINE, CA
ClearPoint Neuro Announces Transition Plan for New Chief Financial Officer Danilo D'Alessandro will Succeed Harold A. Hurwitz who Plans to Retire in 2021 IRVINE, CA, September 14, 2020 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that global medical device
Read more →CLPTClearPoint Neuro Reports Second Quarter 2020 Results Revenue Reaches $2.5 million Amid COVID-19 Pandemic IRVINE, CA
Reports Second Quarter 2020 Results Reaches $2.5 million Amid COVID-19 Pandemic IRVINE, CA, August 12, 2020 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) today announced financial results for its second fiscal quarter and six months ended June 30, 2020. - Three Months Ended June 3
Read more →CLPTClearPoint Neuro to Announce Second Quarter 2020 Results on August 12
IRVINE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 second quarter, which ended June 30, 2020, on Wednesday, August 12, 2020 after the market close. The Company
Read more →CLPTClearPoint Neuro Reports First Quarter 2020 Results Company Provides Update on Effects of COVID-19 Pandemic IRVINE, CA
ClearPoint Neuro Reports First Quarter 2020 Results Update on Effects of COVID-19 Pandemic CA, May 12, 2020 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) today announced financial results for its first fiscal quarter ended March 31, 2020. revenues were approximately $3.1 million an
Read more →CLPTClearPoint Neuro to Announce First Quarter 2020 Results on May 12
IRVINE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 first quarter, which ended March 31, 2020, on Tuesday, May 12, 2020 after the market close. Investors and an
Read more →CLPTthe Company's actual results are described in the "Risk Factors" section of the Company's Annual Report
BIOTECHNOLOGY LEADER AND SURGEON DR. MATTHEW KLEIN JOINS CLEARPOINT NEURO BOARD OF DIRECTORS IRVINE, CA, April 17, 2020 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuro's Board of Direct
Read more →CLPTCLEARPOINT NEURO PROVIDES A COVID-19 PANDEMIC UPDATE AND ANNOUNCES PRELIMINARY FIRST QUARTER 2020
CLEARPOINT NEURO PROVIDES A COVID-19 PANDEMIC UPDATE AND ANNOUNCES PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS IRVINE, CA - April 16, 2020 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company") today provided an update with respect to the COVID-19 pandemic and announced
Read more →CLPTClearPoint Neuro, Inc. Announces 2020 Revenue Outlook Ahead of Nasdaq Investor Presentation Today
IRVINE, Calif., Feb. 14, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a leading platform neurosurgery company, today announced a strategic agreement with PTC Therapeutics, Inc. (“PTC”). The scope of the agreement includes hardware, software, cli
Read more →CLPTClearPoint Neuro, Inc. Announces 2020 Revenue Outlook Ahead of Nasdaq Investor Presentation Today New U.S. and European Partnership Agreement with PTC Therapeutics Highlights Growth of ClearPoint Ge
ClearPoint Neuro, Inc. Announces 2020 Revenue Outlook Ahead of Nasdaq Investor Presentation Today New U.S. and European Partnership Agreement with PTC Therapeutics Highlights Growth of ClearPoint Gene Therapy Portfolio IRVINE, CA, February 14, 2020 - ClearPoint Neuro, Inc. (
Read more →CLPTClearPoint Neuro Reports 53% Increase in 2019 Revenue Fourth quarter revenue grows 41%, fifth consecutive quarter of revenue growth IRVINE, CA
ClearPoint Neuro Reports 53% Increase in 2019 Revenue revenue grows 41%, fifth consecutive quarter of revenue growth IRVINE, CA, February 12, 2020 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (formerly, MRI Interventions, Inc.; the "Company") today announced financial results for i
Read more →CLPTMRI Interventions, Inc. Changes Corporate Name to ClearPoint Neuro, Inc. Company To Commence Trading Under Ticker Symbol CLPT on
MRI Interventions, Inc. Changes Corporate Name to ClearPoint Neuro, Inc. Company To Commence Trading Under Ticker Symbol CLPT on February 12, 2020 IRVINE, CA, February 11, 2020 - MRI Interventions, Inc. (Nasdaq: MRIC) (the "Company"), a leading platform neurosurgery company
Read more →CLPTClearPoint Neuro to Announce Fourth Quarter and Full Year 2019 Results February 12
IRVINE, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (formerly, MRI Interventions, Inc.; the “Company”, formerly Nasdaq: MRIC) today announced that it will release financial results for its 2019 fourth quarter and full year, which ended December
Read more →CLPTMRI Interventions, Inc. Closes $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management IRVINE, CA
MRI Interventions, Inc. Closes $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management IRVINE, CA, January 29, 2020 - MRI Interventions, Inc. (Nasdaq: MRIC) (the "Company"), a leading platform neurosurgery company, closed its
Read more →CLPTMRI Interventions, Inc. Obtains a $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management Transaction follows 43% growth in fourth quarter revenue
MRI Interventions, Inc. Obtains a $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management Transaction follows 43% growth in fourth quarter revenue IRVINE, CA, January 13, 2020 - MRI Interventions, Inc. (Nasdaq: MRIC) (the "Co
Read more →CLPTMRI Interventions, Inc. Announces Move to Nasdaq Capital Market
MRI Interventions, Inc. Announces Move to Nasdaq IRVINE, Calif., November 26, 2019 - MRI Interventions, Inc. (NYSE American: MRIC) (the "Company") today announced that it will voluntarily move its stock exchange listing from the NYSE American LLC to the Nasdaq Capital Market.
Read more →CLPTMRI Interventions Reports 62% Increase in 2019 Third Quarter Revenue Performance marks fourth consecutive quarter of record revenue and case volume IRVINE, CA
MRI Interventions Reports 62% Increase in 2019 Third Quarter Revenue marks fourth consecutive quarter of record revenue and case volume IRVINE, CA, November 12, 2019 - MRI Interventions, Inc. (NYSE American: MRIC) (the "Company") today announced financial results for its thir
Read more →CLPTHEALTHCARE VETERAN KRISTINE JOHNSON TO JOIN MRI INTERVENTIONS'
HEALTHCARE VETERAN KRISTINE JOHNSON TO JOIN MRI INTERVENTIONS' BOARD OF DIRECTORS IRVINE, CA, August 6, 2019 - MRI Interventions, Inc. (NYSE American: MRIC) is pleased to announce that B. Kristine Johnson has been appointed to MRI Interventions' Board of Directors, effective
Read more →CLPTMRI Interventions Reports 58% Increase in 2019 Second Quarter Revenue Record $2.6 Million Quarterly Revenue and Case Volume IRVINE, CA
MRI Interventions Reports 58% Increase in 2019 Second Quarter Revenue $2.6 Million Quarterly Revenue and Case Volume IRVINE, CA, August 6, 2019 - MRI Interventions, Inc. (NYSE American: MRIC) (the "Company") today announced financial results for its second fiscal quarter ende
Read more →CLPTMRI Interventions, Inc. Announces Uplisting to NYSE American Stock Will Trade Under Its Existing Symbol MRIC' Starting
MRI Interventions, Inc. Announces Uplisting to NYSE American Stock Will Trade Under Its Existing Symbol MRIC' Starting July 3, 2019 IRVINE, Calif., June 28, 2019 - MRI Interventions, Inc. (OTCQB: MRIC) (the "Company") today announced that its common stock has been approved
Read more →CLPTMRI Interventions Announces Closing of $7.522 Million Private Placement IRVINE, CA
MRI Interventions Announces Closing of $7.522 Million Private Placement IRVINE, CA, May 17, 2019 - MRI Interventions, Inc. (OTCQB: MRIC) today announced the closing on May 17, 2019 of its previously disclosed private placement of shares of common stock, which resulted in gross
Read more →CLPTPTC Therapeutics and MRI Interventions Announce Strategic Investment - $4 million equity investment to advance delivery device R&D for CNS gene therapy portfolio and other company operations - SOUTH PLAINFI
PTC Therapeutics and MRI Interventions Announce Strategic Investment - $4 million equity investment to advance delivery device R&D for CNS gene therapy portfolio and other company operations - SOUTH PLAINFIELD, NJ and IRVINE, CA, May 9, 2019 - PTC Therapeutics, Inc. (NASDAQ
Read more →CLPTMRI Interventions Reports 52% Increase in First Quarter Revenue Record $2.5 million quarterly revenue driven by growth across entire portfolio IRVINE, CA
MRI Interventions Reports 52% Increase in First Quarter Revenue $2.5 million quarterly revenue driven by growth across entire portfolio IRVINE, CA, April 30, 2019 - MRI Interventions, Inc. (OTCQB: MRIC) (the "Company") today announced financial results for its first fiscal qu
Read more →CLPTMRI Interventions Reports 36% Increase in Fourth Quarter Revenue and Record Quarterly ClearPoint Cases Fourth Quarter Cash Burn from Operations Reduced to $600,000 IRVINE, CA
MRI Interventions Reports 36% Increase in Fourth Quarter Revenue and Record Quarterly ClearPoint Cases Quarter Cash Burn from Operations Reduced to $600,000 IRVINE, CA, March 11, 2019 - MRI Interventions, Inc. (OTCQB: MRIC) (the "Company") today announced financial results f
Read more →CLPTMRI Interventions Announces estimated 30% Growth driven by Record Revenue and record clearpoint procedure volume in 2018 Fourth Quarter Irvine, CA
Announces estimated 30% Growth driven by Record Revenue and record clearpoint procedure volume in 2018 Fourth Quarter CA - January 3, 2019 - MRI Interventions, Inc. (OTCQB:MRIC), a platform neurosurgery company with products designed for navigation in procedures for deep brain
Read more →CLPTMRI Interventions Reports Record ClearPoint Cases and Disposable Functional Neurosurgery Revenue in Third Quarter IRVINE, CA
MRI Interventions Reports Record ClearPoint Cases and Disposable Functional Neurosurgery Revenue in Third Quarter IRVINE, CA, November 12, 2018 - MRI Interventions, Inc. (OTCQB: MRIC) (the "Company") today announced financial results for its third fiscal quarter ended Septem
Read more →CLPTMRI Interventions and Clinical Laserthermia Systems (CLS) Announce Collaboration to Develop Next-Generation Navigation and Laser Ablation Platforms for Neurosurgery - UPDATE Under the terms of the agreement
MRI Interventions and Clinical Laserthermia Systems (CLS) Announce Collaboration to Develop Next-Generation Navigation and Laser Ablation Platforms for Neurosurgery - UPDATE Under the terms of the agreement, MRIC acquires worldwide exclusive rights to the platform for use in
Read more →CLPTInvestor Presentation Joe Burnett, President & CEO June 2018 Forward Looking Statements Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statem
Investor Presentation Joe Burnett, President & CEO June 2018 Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Co
Read more →CLPTMRI Interventions Retires Brainlab Debt, Extends 2019 Notes by 18 Months Irvine, CA
MRI Interventions Retires Brainlab Debt, Extends 2019 Notes by 18 Months Irvine, CA - September 25, 2018 - MRI Interventions, Inc. (OTCQB:MRIC), announced today that the company has repaid in full and retired $2.0 million in outstanding debt held by Brainlab AG which was set t
Read more →CLPTMRI Interventions Reports Second Quarter Results Biologics Trials, CE Mark Clearances and FDA Submissions Expand Market Opportunities IRVINE, CA
MRI Interventions Reports Second Quarter Trials, CE Mark Clearances and FDA Submissions Expand Market Opportunities IRVINE, CA, August 14, 2018 - MRI Interventions, Inc. (OTCQB: MRIC) (the "Company") today announced financial results for its second fiscal quarter ended June 30
Read more →CLPTMRI Interventions, Inc. to Webcast at LD Micro Conference
MRI Interventions, Inc. to Webcast at LD IRVINE, Calif., June 4, 2018 - MRI Interventions, Inc. (OTCQB:MRIC) announced that it will webcast its presentation at the 8th annual LD Micro Invitational Conference on Tuesday, June 5. Joe Burnett, Chief Executive Officer, is schedule
Read more →CLPTFIRST QUARTER RESULTS MRI Interventions Reports First Quarter Results, New Strategic Initiatives to Further Growth IRVINE, CA
MRI Interventions Reports First Quarter Results, New Strategic Initiatives to Further Growth IRVINE, CA, May 15, 2018 - MRI Interventions, Inc. (OTCQB: MRIC) (the "Company") today announced financial results for its first fiscal quarter ended March 31, 2018. First Quarter 201
Read more →CLPTInvestor Presentation Joe Burnett, President & CEO April 2018 2018 MRI INTERVENTIONS, INC. | 1 Forward Looking Statements Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies
Procedure volume has grown 43%+ CAGR from 2013-2017 80%+ of current revenue from single-use, high-margin disposables Pipeline of new revenue streams from product improvements, new drug therapy trials, and standalone therapy products Total potential addressable market > $1B for ou
Read more →CLPTMRI Interventions, Inc. Reports 34% Year-Over-Year Increase in Functional Neurology Revenues, 50% increase in Capital Sales Record 629 ClearPoint Procedures Performed in 2017 New Initiatives Position for Further Growth i
MRI Interventions, Inc. Reports 34% Year-Over-Year Increase in Functional Neurology Revenues, 50% increase in Capital Sales ClearPoint Procedures Performed in 2017 Position for Further Growth in 2018 IRVINE, CA, March 15, 2018 - MRI Interventions, Inc. (OTCQB: MRIC) (the "C
Read more →CLPTMRI Interventions, Inc. Announces Record 629 ClearPoint Cases in 2017 2017 Functional Neurology Product Revenue Increases 34%, Total Revenue Increases 28% Over 2016 IRVINE, CA
MRI Interventions, Inc. Announces Record 629 ClearPoint Cases in 2017 2017 Functional Neurology Product Revenue Increases 34%, Total Revenue Increases 28% Over 2016 IRVINE, CA, February 6, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medi
Read more →CLPTMRI Interventions, Inc. Reports 26% Year-Over-Year Increase in Third Quarter Procedures Gross Margin Increases to 60% Record 469 ClearPoint Procedures Performed Year-to-Date IRVINE, CA
Interventions, Inc. Reports 26% Year-Over-Year Increase in Third Quarter Procedures Margin Increases to 60% 469 ClearPoint Procedures Performed Year-to-Date CA, November 6, 2017 - MRI Interventions, Inc. (OTCQB: MRIC) (the "Company") today announced financial results for the
Read more →CLPTMRI Interventions Announces Joseph Burnett As New President and CEO Leadership Transition Intended to Accelerate Next Phase of Growth IRVINE, CA
MRI Interventions Announces Joseph Burnett As New President and CEO Transition Intended to Accelerate Next Phase of Growth IRVINE, CA, October 9, 2017 - MRI Interventions, Inc. (OTCQB: MRIC) today announced the appointment of Joseph Burnett as President and CEO, effective Nov
Read more →CLPTInvestor Presentation October 2017 2017 MRI INTERVENTIONS, INC. | 1 Forward Looking Statements Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking
Presentation October 2017 2017 MRI INTERVENTIONS, INC. | 1 Forward Looking Statements Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Stat
Read more →CLPTMRI Interventions, Inc. Reports 79% Revenue Increase and Record Treatments in Second Quarter 2017 Transformative financing completed during the quarter IRVINE, CA
MRI Interventions, Inc. Reports 79% Revenue Increase and Record Treatments in financing completed during the quarter IRVINE, CA, August 1, 2017 - MRI Interventions, Inc. (OTCQB: MRIC) (the "Company") today announced financial results for the second quarter ended June 30, 2017
Read more →CLPTMRI Interventions Announces Record Second Quarter ClearPoint System Procedures, And a 79% Year-Over-Year Revenue Increase Ninth Consecutive Quarter of ClearPoint System Procedure Growth IRVINE, CA
MRI Interventions Announces Record Second Quarter ClearPoint System Procedures, And a 79% Year-Over-Year Revenue Increase Ninth Consecutive Quarter of ClearPoint System Procedure Growth IRVINE, CA - July 11, 2017 - MRI Interventions, Inc. (OTCQB: MRIC) (the "Company"), toda
Read more →CLPTMRI Interventions Announces Closing of $13.25 Million Private Placement IRVINE, CA
MRI Interventions Announces Closing of $13.25 Million Private Placement IRVINE, CA, May 30, 2017 - MRI Interventions, Inc. (OTCQB: MRIC) today announced the closing on May 26, 2017 of its previously disclosed private placement of equity units, which resulted in gross proceeds
Read more →CLPTMRI Interventions Announces $13.25 Million Private Placement Offering Transformative for the Company IRVINE, CA
MRI Interventions Announces $13.25 Million Offering Transformative for the Company IRVINE, CA, May 25, 2017 - MRI Interventions, Inc. (OTCQB: MRIC) today announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in g
Read more →CLPTHEALTHCARE VETERAN JOHN FLETCHER JOINS MRI INTERVENTIONS' BOARD OF DIRECTORS IRVINE, CA, May 11 , 2017 - MRI Interventions, Inc. (OTCQB: MRIC) is pleased to announce that John Fletcher has been appo
HEALTHCARE VETERAN JOHN FLETCHER JOINS MRI INTERVENTIONS' BOARD OF DIRECTORS 11, 2017 - MRI Interventions, Inc. (OTCQB: MRIC) is pleased to announce that John Fletcher has been appointed to MRI Interventions' Board of Directors. Mr. Fletcher, founder and managing partner of Fl
Read more →CLPTInvestor Presentation May 2017 2017 MRI INTERVENTIONS, INC. | 1 Forward Looking Statements Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking sta
Presentation May 2017 2017 MRI INTERVENTIONS, INC. | 1 herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future even
Read more →CLPTMRI INTERVENTIONS, INC. Condensed Consolidated Statements of Cash Flows (Unaudited) For The Three Months Ended
MRI INTERVENTIONS, INC. ANNOUNCES 2017 Company Achieves Quarterly Records for Revenue and ClearPoint System Procedures IRVINE, CA, April 27, 2017 - MRI Interventions, Inc. (OTCQB: MRIC) (the "Company") today announced financial results for the first quarter ended March 31, 20
Read more →CLPTMRI Interventions Announces License and Collaboration Agreement with Acoustic MedSystems, Adding Ultrasound Ablation Technology to MRIC's Platform Companies to combine existing real-time MRI guidanc
MRI Interventions Announces License and Collaboration Agreement with Acoustic MedSystems, Adding Ultrasound Ablation Technology to MRIC's Platform Companies to combine existing real-time MRI guidance and novel ultrasound ablation technologies for treatment of pancreatic canc
Read more →CLPTClearPoint Neuro Navigation System’s Real-time MRI Guided Platform to be Featured at AANS Practical Clinics for Fourth Consecutive Year
IRVINE, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint® Neuro Navigation System will be featured in the laser ablation hands-on Practical Clinic during the Annual Meeting of the American Association of Neurologi
Read more →CLPTMRI INTERVENTIONS ANNOUNCES RECORD QUARTERLY REVENUE, RECORD CLEARPOINT SYSTEM PROCEDURES IN 2017 FIRST QUARTER Company Achieves Eighth Consecutive Quarter of ClearPoint System Procedure Growth IRVI
MRI INTERVENTIONS ANNOUNCES RECORD QUARTERLY REVENUE, RECORD CLEARPOINT SYSTEM PROCEDURES IN 2017 FIRST QUARTER Company Achieves Eighth Consecutive Quarter of ClearPoint System Procedure Growth 6, 2017 - MRI Interventions, Inc. (OTCQB: MRIC) today announced preliminary result
Read more →CLPTHarold A. Hurwitz, Chief Financial Officer (949) 900-6833 For Immediate Release MRI INTERVENTIONS, INC. ANNOUNCES 2016 FOURTH QUARTER AND FULL YEAR RESULTS Key 2016 accomplishments include year-over-year increas
Harold A. Hurwitz, Chief Financial Officer INTERVENTIONS, INC. ANNOUNCES 2016 FOURTH QUARTER 2016 accomplishments include year-over-year increases in revenue of 25%, ClearPoint procedures of 32% and disposable product revenue of 36% CA, February 28, 2017 - MRI Interventions,
Read more →CLPTHarold A. Hurwitz, Chief Financial Officer (949) 900-6833 For Immediate Release MRI INTERVENTIONS, INC. ANNOUNCES YEAR-END UPDATE, INCLUDING 2016 FOURTH QUARTER AND FULL YEAR REVENUES 2016 Disposable Product Rev
A. Hurwitz, Chief Financial Officer MRI INTERVENTIONS, INC. ANNOUNCES YEAR-END 2016 FOURTH QUARTER AND FULL YEAR REVENUES 2016 Disposable Product Revenues Increase Continued Progress in Clinical Programs Utilizing MRIC's ClearPoint System Recently Reported 24, 2017 - MRI In
Read more →CLPTHarold A. Hurwitz, Chief Financial Officer (949) 900-6833 For Immediate Release MRI INTERVENTIONS, INC. ANNOUNCES 2016 THIRD QUARTER AND NINE MONTH RESULTS Highlights Include: Record Revenues of $1.6 Million; Re
A. Hurwitz, Chief Financial Officer MRI INTERVENTIONS, INC. ANNOUNCES 2016 AND NINE MONTH RESULTS Highlights Include: Record Revenues of $1.6 Million; Record Number of ClearPoint Procedures; and Continued Improvement in Operating Loss and Cash Utilization IRVINE, CA, Novem
Read more →CLPTMRI Interventions Announces $6 Million Private Placement Includes $4.25 million of gross cash proceeds and the conversion of $1.75 million in secured debt IRVINE, CA
Interventions Announces $6 Million Private Placement $4.25 million of gross cash proceeds of $1.75 million in secured debt IRVINE, CA, August 31, 2016 - MRI Interventions, Inc. (OTCQB: MRIC) today announced it has entered into a definitive securities purchase agreement with a
Read more →CLPTTicker: MRIC Investor Presentation August 18, Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI 2016 MRI INTERVENTIONS, INC. | 1 Forward Looking Statements Certain statements in th
Ticker: MRIC Investor Presentation August 18, Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI 2016 MRI INTERVENTIONS, INC. | 1 Looking Statements Certain statements in this presentation may constitute forward-looking statements within
Read more →CLPTHarold A. Hurwitz, Chief Financial Officer (949) 900-6833 For Immediate Release MRI INTERVENTIONS, INC. ANNOUNCES 2016 SECOND QUARTER AND SIX MONTH RESULTS Second Quarter Highlights Include Record Number of Proc
A. Hurwitz, Chief Financial Officer MRI INTERVENTIONS, INC. ANNOUNCES 2016 AND SIX MONTH RESULTS Second Quarter Highlights Include Record Number of Procedures and 52% Year-Over-Year Growth in Disposable IRVINE, CA, August 15, 2016 - MRI Interventions, Inc. (OTCQB: MRICD) t
Read more →CLPTTicker: MRIC Investor Presentation
Investor Presentation Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI 2016 MRI INTERVENTIONS, INC. | 1 Forward Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of S
Read more →CLPTHarold A. Hurwitz, Chief Financial Officer (949) 900-6833 For Immediate Release MRI INTERVENTIONS, INC. ANNOUNCES 2016 FIRST QUARTER RESULTS Company Sets Quarterly Records in Number of ClearPoint Procedures and
Harold A. Hurwitz, Chief Financial Officer MRI INTERVENTIONS, INC. ANNOUNCES 2016 FIRST QUARTER RESULTS Company Sets Quarterly Records in Number of ClearPoint Procedures and Disposable Product Revenues IRVINE, CA, April 28, 2016 - MRI Interventions, Inc. (OTCQB: MRIC) toda
Read more →CLPTHarold A. Hurwitz, Chief Financial Officer (949) 900-6833 For Immediate Release MRI INTERVENTIONS, INC. ANNOUNCES 2015 FOURTH QUARTER AND FULL YEAR RESULTS Record-Setting Revenues Achieved in Fourth Quarter 2015
Harold A. Hurwitz, Chief Financial Officer MRI INTERVENTIONS, INC. ANNOUNCES 2015 AND FULL YEAR RESULTS Record-Setting Revenues Achieved in IRVINE, CA, March 23, 2016 - MRI Interventions, Inc. (OTCQB: MRIC) today announced financial results for the fourth quarter and full ye
Read more →CLPTMRI Interventions, Inc. Announces Agreement to Restructure Brainlab AG Senior Secured Note Agreement Includes an Equity Investment, License Agreement, Restructured Note and Interest Payment
MRI Interventions, Inc. Announces Agreement Restructure Brainlab AG Senior Secured Note Includes an Equity Investment, License Agreement, Restructured Note and Interest Payment March 22, 2016 (GLOBE NEWSWIRE) - MRI Interventions, Inc. (OTCQB: MRIC) today announced it has reac
Read more →CLPTHarold A. Hurwitz, Chief Financial Officer (949) 900-6833 For Immediate Release MRI INTERVENTIONS, INC. ANNOUNCES 2015
Harold A. Hurwitz, Chief Financial Officer MRI INTERVENTIONS, INC. ANNOUNCES 2015 FOURTH QUARTER AND FULL YEAR REVENUES January 7, 2016 - MRI Interventions, Inc. (OTCQB: MRIC) today announced its revenues for the fourth quarter and full year ended December 31, 2015. million
Read more →CLPTMRI Interventions Announces $5.3 Million Private Placement IRVINE, CA
MRI Interventions Announces $5.3 Million IRVINE, CA, December 15, 2015 - MRI Interventions, Inc. (OTCQB: MRIC) announced it has entered into a definitive securities purchase agreement with a group of investors which will result in gross proceeds to MRI Interventions of approxi
Read more →CLPTTicker: MRIC Investor Presentation September, 2015 Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI 2015 MRI INTERVENTIONS, INC. | 1 Forward Looking Statements Certain statements
(1) Responsive neurostimulation device (RNS) (2) Potential Annual ClearPoint Procedures based upon 5% of prevalence and 85% of incidence; Potential Annual ClearPoint Procedures for brain tumors based on market research conducted by a third party on behalf of MRI Interventions. 20
Read more →CLPTFrank Grillo Chief Executive Officer (949) 900-6833 MRI Interventions Reports 2015 First Quarter Financial Results IRVINE, Calif., April 30 , 2015 (GLOBE NEWSWIRE) -- MRI Interventions , Inc . (OTCQB:MRIC) annou
MRI Interventions Reports 2015 First Quarter Financial Results IRVINE, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) announced today its financial results for the first quarter ended March 31, 2015. "This growth, both in revenues and accounts,
Read more →CLPTMRI Interventions' New Chief Financial Officer Harold A. Hurwitz Brings Considerable Medical Device Finance Experience to Growing Company
MRI Interventions' New Chief Financial Officer Harold A. Hurwitz Brings Considerable Medical Device Finance Experience to Growing Company IRVINE, California, March 17, 2015 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB: MRIC) is pleased to announce that seasoned medical dev
Read more →CLPTMRI INTERVENTIONS REPORTS 2014
MRI INTERVENTIONS REPORTS 2014 FINANCIAL RESULTS IRVINE, Calif., March 5, 2015 - MRI Interventions, Inc. (OTCQB: MRIC), a commercial stage medical device company focused on creating innovative platforms for performing the next generation of minimally invasive surgical procedures
Read more →CLPTMRI Interventions Announces $ 10.2 Million Private Placement IRVINE, CA
MRI Interventions Announces $10.2 Million Private Placement IRVINE, CA, December 19, 2014 - MRI Interventions, Inc. (OTCQB: MRIC) today announced it has entered into a definitive securities purchase agreement with a group of investors for the private placement of approximately 1
Read more →CLPTMRI INTERVENTIONS ANNOUNCES THIRD QUARTER 2014
MRI INTERVENTIONS ANNOUNCES THIRD QUARTER 2014 FINANCIAL RESULTS IRVINE, CA., November 13, 2014 - MRI Interventions, Inc. (OTCQB: MRIC), a commercial stage medical device company focused on creating innovative platforms for performing the next generation of minimally invasive s
Read more →CLPTMRI Interventions Provides Perspective on Third Quarter, as Frank Grillo Assumes Leadership IRVINE , CA.
MRI Interventions Provides Perspective on Third Quarter, as Frank Grillo Assumes Leadership IRVINE, CA., October 6, 2014 - MRI Interventions, Inc. (OTCQB: MRIC), maker of the innovative ClearPoint neuro navigation system, today welcomed Frank Grillo as its new President and CEO-
Read more →CLPTMRI Interventions Announces Frank Grillo, Intuitive Surgical Executive, to Become CEO and Kimble Jenkins to Become Executive Chairman
MRI Interventions Announces Frank Grillo, Intuitive Surgical Executive, to Become CEO and Kimble Jenkins to Become Executive Chairman IRVINE, California, September 11, 2014 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB: MRIC) today announced that medical device veteran Fran
Read more →CLPTMRI Interventions Welcomes Pascal E.R. Girin to Board of Directors Newest Director Brings Additional Medical Device Management Experience, Executive Perspective to Board
MRI Interventions Welcomes Pascal E.R. Girin to Board of Directors Newest Director Brings Additional Medical Device Management Experience, Executive Perspective to Board IRVINE, California, September 3, 2014 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB: MRIC) today announ
Read more →CLPTDear Fellow Stockholders, On the heels of our Q2 2014 earnings release, I am pleased to provide you with a positive report about the opportunities before us, our improving results and how we're continuing to build value
Dear Fellow Stockholders, On the heels of our Q2 2014 earnings release, I am pleased to provide you with a positive report about the opportunities before us, our improving results and how we're continuing to build value for stockholders. The Market Opportunity Is Very Attractiv
Read more →CLPTMRI INTERVENTIONS ANNOUNCES SECOND QUARTER 2014 FINANCIAL RESULTS Reports record total product revenues for the quarter Reports record disposable product revenues for the quarter Reports eighth consecutive quarter of seq
MRI INTERVENTIONS ANNOUNCES SECOND QUARTER 2014 FINANCIAL RESULTS MEMPHIS, Tenn., August 7, 2014 - MRI Interventions, Inc. (OTCQB: MRIC), a commercial stage medical device company focused on creating innovative platforms for performing the next generation of minimally invasive
Read more →CLPTMRI INTERVENTIONS ANNOUNCES FIRST QUARTER 2014 FINANCIAL RESULTS Reports total revenues of $823,000 Reports fourth consecutive quarter of reduced cash burn Announces involvement in sixth drug delivery trial
MRI INTERVENTIONS ANNOUNCES FIRST QUARTER 2014 FINANCIAL RESULTS MEMPHIS, Tenn., May 8, 2014 - MRI Interventions, Inc. (OTCQB: MRIC), a commercial stage medical device company focused on creating innovative platforms for performing the next generation of minimally invasive surgi
Read more →Competitive Position
How CLPT ranks across every disease it competes inCompetitive Position is a premium feature
See how CLPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial